Liver disease · Phase 1
Pemvidutide: MASLD extension
NCT05292911 ↗ · Extension or follow-up
What was tested?
Continued pemvidutide or placebo in eligible completers of a preceding 12-week MASLD trial. ↗
Registered primary question: The number of participants with treatment-emergent adverse events through day 110. ↗
What the reviewed report found
Journal year 2025 · Article summary reviewed 2026-09-15
At 24 weeks, reported relative liver-fat reductions were 56.3%, 75.2% and 76.4% in active groups versus 14.0% with placebo.↗
Keep in context: The registry primary outcome concerns adverse events; the publication calls liver-fat change its primary efficacy outcome. This is an extension cohort, and MRI liver fat is not a biopsy-based fibrosis outcome. ↗↗
What a closer reading adds
Selected full-text sections checked 2026-09-20. These notes add context to the earlier article summary; they are not a complete risk-of-bias assessment.
How the extension population was selected
Of 94 people treated in the parent study, 83 completed treatment, 66 consented to continue, and 64 entered the extension. Participants with more advanced liver disease were excluded, limiting extrapolation to that population. Full text ↗ · Indexed abstract ↗
Sections: Trial design and participant selection; Trial participants; Discussion.
What the measurements can establish
The paper describes imaging and blood-marker outcomes. Its discussion says the suggested tissue-level improvements require confirmation in a biopsy-driven trial; this reading does not convert liver-fat changes into proven fibrosis improvement. Full text ↗ · Indexed abstract ↗
Sections: Efficacy endpoints; Discussion.
Participants, design, limitations and sources
Registry snapshot
- Registry enrollment
- 64 · reported actual
- Registry status
- Completed
- Allocation and masking
- Randomized · Double
- Design
- Parallel
- Eligible ages
- 18 Years to 65 Years
- Registry results
- Not posted in this snapshot
Registry source ↗ · Updated 2023-07-27; retrieved 2026-09-20. Registry enrollment is not necessarily the analyzed sample in a publication. Posted registry results and published article results are separate.
MASLD extension
- Design in the report
- Double-blind extension of a preceding randomized trial; NCT05292911.↗
- Participants in the report
- 64 participants from the earlier 94-participant study continued; this is not a new independently randomized cohort.↗
- Limitations
- Selective extension participation can bias interpretation. MRI liver fat is not the same as histologic fibrosis improvement or patient-important liver outcomes.↗
This reading covers the article abstract and record metadata. Read its preserved Human Evidence Review →
How the study identity and sources were checked
Study context checked 2026-09-20. Existing article summaries keep their original review dates. This is a selected study reading, not a complete literature or full-text appraisal.
Registry
Extension of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With (NAFLD) ↗
Protocol identifier: ALT-801-106. Sponsor: Altimmune, Inc..
Retrieved 2026-09-20; SHA-256 a7108c842bf778f2b9bb1c8be2c1daa41097395e34fff498e1d28635384199d6.
PMID 41113119
Exact trial identity is declared in PubMed’s ClinicalTrials.gov databank field. The registry independently labels this reference DERIVED. These source labels do not establish that every result in a paper applies to this trial.
Identity metadata retrieved 2026-09-20. EFetch batch XML; locate MedlineCitation/PMID 41113119. SHA-256 adc8edd8b150d99a3641ddbc74c59db6916cf35d9d6246838aaff2cc195ae1cb.
Scientific summary uses the original 2026-09-15 source snapshot: SHA-256 d02cc11ccdebbc2d2d7f2dcd803d72fac82dab958b1ca103096a9f2b94a061c5.
Selected full text: PMC12529369
Retrieved 2026-09-20; SHA-256 09c6267d051dca6790e48cda688cf681e282ea25bbfd909cede12bb4f78f672c. Section identifiers and hashes are included in the cited study data.